Live
BioPharma DiveVerge, following trial failure, rebrands its AI drug discovery ambitionsBioPharma DiveFDA delays decision on AstraZeneca breast cancer pillFierceBiotechKordata Dynamics launches with neural-focused AI clinical trial modelClinical OMICsDual CA19-9 Threshold Improves Risk Stratification in Pancreatic CancerClinical OMICsCD169-Positive Macrophages Attacking Melanoma Imaged in Living TissueClinical OMICsGuardant Nabs Key ACS Nod and Liquid Biopsy ApprovalClinical OMICsAI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy ResponseBioPharma DiveCardio drugmaker Kardigan plans to go publicBioPharma DiveKailera’s three-pronged obesity shot shows promise in early trialBioPharma DiveApogee eczema drugs gets Blackstone backing, heads to Phase 3Endpoints NewsAstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as WaveEndpoints NewsApogee secures Blackstone capital to move Dupixent rival into Phase 3
Waters Apr 11, 2026

Waters Corporation (NYSE: WAT) Reports First Quarter 2022 Financial Results - ADVFN

Waters Corporation (NYSE: WAT) Reports First Quarter 2022 Financial Results - ADVFN

Original
Body unavailable. Use the original source.